Stoke Therapeutics Inc.
NASDAQ · STOK·Bedford, MA·Mid-cap·Phase 3
Develops antisense oligonucleotide therapies using its TANGO platform to upregulate protein expression in haploinsufficiency-driven diseases. Lead asset zorevunersen is in a Phase 3 registrational study for Dravet syndrome, with data expected mid-2027.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Stoke Therapeutics JP Morgan 2026 | JPM Healthcare | January 13, 2026 | 19 |